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Review
Idiopathic Parkinson’s disease (PD) is a 
  progressive neuro  degenerative disorder with 
a slow onset, and compared with the famil-
ial forms of the disease, it is associated with 
advanced age (> 55 years of age). The four 
cardinal signs of idiopathic PD are tremor 
at rest, bradykinesia (hypokinesia and akine-
sia), rigidity, and postural instability (Jankovic 
2008; Lees et al. 2009; Tolosa et al. 2006). 
The diagnosis of idiopathic PD is typically 
based on the presence of two or more of the 
four cardinal signs and a response to l-dopa 
therapy. Unilateral tremor of the hand at rest 
with a frequency of 4–6 Hz is the earliest 
and most easily recognized symptom of PD. 
Autopsy-based studies have shown that the 
percentage of patients with confirmed PD 
diagnosis who exhibited resting tremor ranges 
from 76–100% (Hughes et al. 1993; Louis 
et al. 1997; Rajput et al. 1991).
Bradykinesia is defined by slowness of 
movements or difficulty in initiating and 
executing movement, and it is one of the 
essential signs used to diagnose idiopathic 
PD (Lees et al. 2009). Bradykinesia appears 
to correlate with the degree of dopamine defi-
ciency in the caudate and putamen (striatum) 
(Vingerhoets et al. 1997). Rigidity is charac-
terized by increased resistance of the limbs 
and is the result of the muscles becoming 
tensed and contracted so that the person feels 
stiff and weak. Postural instability is the loss 
of postural reflexes, and this occurs in the late 
stages of the disease. Postural instability causes 
patients to develop a forward or backward 
lean that causes them to fall. As the disease 
progresses, walking is affected, and patients 
walk in quick, small steps like they are hurry-
ing forward in order to maintain balance.
Although the clinical diagnosis of PD is 
based on a combination of the four cardinal 
motor signs, other parkinsonian disorders 
also express many of these signs (Tolosa et al. 
2006), and a definite diagnosis of PD requires 
neuro  pathological confirmation (Gelb et al. 
1999). It has been estimated that > 10% of PD 
cases can be diagnosed incorrectly by move-
ment disorder specialists when clinical signs 
are the only basis for diagnosis (Hughes et al. 
2002). Consistent with the known deficiency 
of dopamine in the striatum, the clinical symp-
toms of PD are significantly alleviated with 
l-dopa therapy, the precursor substrate for the 
synthesis of dopamine, the chemical that is 
decreased in PD (Savitt et al. 2006). This is 
important information when one examines 
the hypothesis that manganese (Mn)-induced 
parkinsonism involves nigrostriatal dopamine 
neuron degeneration.
Molecular imaging is a useful strategy 
for the diagnosis of PD and has provided 
extensive evidence that PD patients exhibit 
decreased levels of presynaptic dopamine neu-
ron terminal markers in the striatum (Felicio 
et al. 2009). This is consistent with the loss of 
dopamine terminals as a result of degeneration 
of neuronal cell bodies in the substantia nigra 
pars compacta (SNpc) (Figure 1). Single pho-
ton emission computed tomography (SPECT) 
and positron emission tomography (PET) 
studies have shown that PD patients exhibit 
decreased levels of dopamine transporters 
(DATs) and vesicular monoamine transporter 
type 2 (VMAT2) and reduced activity of dopa 
decarboxylase as measured by the conversion 
of l-dopa to dopamine in the striatum using 
[18F]-fluoro-dopa PET (Felicio et al. 2009). 
Postsynaptic D2-dopamine receptors (D2Rs) 
either are not affected or are increased in the 
striatum of untreated PD patients (Antonini 
et al. 1994; Brooks et al. 1992; Rinne et al. 
1990). Similar changes in these markers have 
been documented in a nonhuman primate 
model of PD (Chen et al. 2008).
A major discovery in understanding the 
molecular basis of PD came about when a defi-
cit in the concentration of the neuro  transmitter 
dopamine was discovered in the striatum of 
brain samples from PD patients (Ehringer and 
Hornykiewicz 1960; Hornykiewicz 2006). 
Scientists now know that a marked loss of dop-
amine-containing neurons in the SNpc results 
in decreased dopamine levels in the caudate 
and putamen (Savitt et al. 2006). A hallmark 
neuro  pathological feature of SNpc dopamine 
neurons in PD is proteinacious intra  neuronal 
aggregations called Lewy bodies that seem to be 
associated with dopamine neuron degeneration 
(Dauer and Przedborski 2003; Wakabayashi 
et al. 2007).
In summary, idiopathic PD patients 
exhibit resting tremor, bradykinesia, rigid-
ity, and postural instability that is the result 
of decreased dopamine concentrations in the 
caudate and putamen from the degeneration 
of dopamine neurons in the SNpc that project 
to these brain regions (Figure 1). The early 
clinical symptoms of PD subjects are markedly 
alleviated by l-dopa therapy. The loss of dopa-
mine neuron markers in the brain of persons 
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with PD can be visualized and quantitatively 
measured using state-of-the-art neuro  imaging 
techniques such as PET and SPECT.
Idiopathic PD and Mn-Induced 
Parkinsonism: The Early 
Writings of James Parkinson 
and John Couper
In 1817, the physician James Parkinson pub-
lished the first description of a neuro  logical 
disorder that is now recognized by his name, 
Parkinson’s disease (Parkinson 1817). His 
monograph, titled An Essay on the Shaking 
Palsy, describes five cases with shaking palsy, 
a term that was vaguely employed by medical 
writers at the time. He commented that 
[T]he first symptoms perceived are, a slight sense 
of weakness, with a proneness to trembling in 
some particular part; sometimes in the head, but 
most commonly in one of the hands and arms. 
These symptoms gradually increase in the part first 
affected; and at an uncertain period, but seldom 
in less than twelve months or more, the morbid 
influence is felt in some other part. Thus assuming 
one of the hands and arms to be first attacked, the 
other, at this period becomes similarly affected. 
Parkinson went on to say that as the disease 
proceeds, “walking becomes a task which can-
not be performed without considerable atten-
tion.” As the malady proceeds, 
The propensity to lean forward becomes invinci-
ble, and the patient is thereby forced to step on the 
toes and fore part of the feet, whilst the upper part 
of the body is thrown so far forward as to render it 
difficult to avoid falling on the face . . . irresistibly 
impelled to take much quicker and shorter steps, 
and thereby to adopt unwillingly a running pace.
He then described the later stages, 
As the disease proceeds toward its last stage, the 
trunk is almost permanently bowed, the muscu-
lar power is more decidedly diminished, and the 
tremulous agitation becomes violent. . . His words 
are now scarcely intelligible, 
and he is no longer able to feed himself. “The 
chin is now almost immoveably bent down 
upon the sternum” . . . with the saliva contin-
ually trickling from the mouth. “The power of 
articulation is lost.”
Twenty years after the essay by James 
Parkinson, John Couper described the first 
symptoms of Mn toxicity in humans (Couper 
1837). The observations made in this brief 
essay are important in order to understand the 
working conditions and the symptoms of Mn 
intoxication in humans. A comparison of the 
two essays makes it clear how the two condi-
tions are similar and how they are different. 
Couper wrote, 
In the chemical works of Charles Tennant and 
Co., a considerable number of men are employed 
in grinding the black oxide of manganese, to be 
employed in the manufacture of bleaching pow-
der. The surface of their bodies is of course con-
stantly covered with the manganese; the air which 
they breathe is loaded with it in the form of fine 
powder, and they are ever exposed, from neglect 
of cleanliness, to swallow portions of it along with 
their food.
It is clear from this description that working 
conditions were very hazardous and personal 
hygiene was poor. As a result, these workers 
were exposed to extremely high concentra-
tions of Mn on a daily basis. 
In the description of the workers who 
were affected by Mn poisoning, Couper went 
on to say that, 
The loss of power is most apparent in the lower 
extremities, which are so considerably affected 
that the patient staggers, and inclines to run for-
ward when he attempts to walk. The arms are 
also weakened, but only to a small extent. The 
patient complains that in speaking he cannot make 
himself heard by persons at a moderate distance, as 
formerly; and the inability seems to depend, not 
on any defect of articulation, but on weakness of 
voice. There is no deficiency of sensibility in any 
part of the body; the intellect and external senses 
are unimpaired; but there is an obvious expres-
sion of vacancy in the countenance, apparently 
from the paralyzed state of the muscles of the face. 
From the same cause the saliva is apt to escape 
from the mouth, especially during speaking. There 
is no tremor in any part of the body.
A comparison of the two essays indi-
cates that certain symptoms are similar and 
some are different from those in PD. The 
Mn-exposed workers exhibited gait distur-
bance, a propensity to fall, masked face, hypo-
phonia and dysphonia, and drooling. The 
absence of resting tremor, a prominent and 
early cardinal sign of PD patients, as initially 
described by James Parkinson, is a distin-
guishing observation that is different from PD 
in these workers heavily exposed to Mn.
Since the initial observations by Couper, 
other reports in the early 1900s noted the 
toxic effects of Mn from occupational expo-
sures but, compared with PD, the number 
of studies is rather limited. The description 
of these subsequent Mn cases supported the 
initial observations by Couper but also added 
additional symptoms such as micrographia, 
dystonia (cock gait), and action and pos-
tural tremor (Table 1; for reference to these 
early cases, see Lee 2000; Perl and Olanow 
2007). Table 1 outlines the motor symptoms 
from the literature related to occupational 
Mn exposures and other human conditions 
in which Mn levels are markedly increased in 
the brain, and the motor symptoms in idio-
pathic PD. The conclusion from these reports 
is that, although several of the clinical signs 
between PD and Mn-induced parkinsonism 
are similar, in Mn-induced parkinsonism, 
unlike in PD, there is an absence of resting 
Figure 1. (A) Schematic depicting the different brain structures comprising the basal ganglia (labeled in the right hemisphere). The left hemisphere shows the nigrostri-
atal dopamine fibers whose cell bodies are located in the substantia nigra (SN) and innervate the caudate and putamen. These are the axonal projections that degener-
ate in Parksinson’s disease. T1-weighted MRI at the level of the globus pallidus of a control nonhuman primate brain (B; boxed areas) and a   nonhuman primate brain 
exposed to Mn (C). Note the increase in signal intensity (white areas) in the Mn-exposed animal (C) relative to the control animal (B). SNT,   subthalamic nucleus.Manganese-induced parkinsonism
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tremor and the lack of a response to l-dopa. 
Also, the progression of Mn-induced parkin-
sonism appears to be a gait disorder of early 
onset with dystonia that occurs much later in 
the slow progression of the movement abnor-
malities in PD.
Mn-Induced Parkinsonism from 
Human Conditions Not Related 
to Occupational Exposures
Besides occupational exposures, other con-
ditions have been shown to increase accu-
mulation of Mn in the brain and have been 
valuable sources of information in under-
standing Mn-induced neuro  logical dysfunc-
tion, including parkinsonism.
Psychostimulant drug abusers: ephedron. 
Recently, there have been a number of reports, 
primarily originating from Eastern European 
countries and Russia, of young addicts afflicted 
with an atypical form of parkinsonism (de Bie 
et al. 2007; Meral et al. 2007; Sanotsky et al. 
2007; Selikhova et al. 2008; Sikk et al. 2007; 
Stepens et al. 2008; Varlibas et al. 2009) 
(Table 1). This form of parkinsonism is the 
result of intravenous injections of a psycho-
stimulant drug called “ephedrone” or “Russian 
cocktail,” a drug in which ephedrine is oxi-
dized using potassium permanganate and ace-
tic acid (Sanotsky et al. 2007; Stepens et al. 
2008). Typically, this homemade chemical 
mixture is not purified before intravenous 
injection, so milligram to gram amounts 
of Mn are injected with multiple injections 
occurring during the course of weeks and 
months. Normal Mn concentrations in whole 
blood are ≤ 10–12 μg/L, but the blood Mn 
concentrations in these young addicts have 
been measured at levels as high as 2,000–
3,000 μg/L (Stepens et al. 2008; Varlibas et al. 
2009). Consistent with the fact that high con-
centrations of Mn are injected, most of these 
individuals exhibit bilateral T1-weighted mag-
netic resonance imaging (MRI) hyperintensive 
signals in the basal ganglia and other brain 
regions reflecting Mn accumulation (Figure 1, 
Table 2).
The parkinsonian signs in these young 
drug-abuse subjects are consistent with 
those in occupationally exposed Mn workers 
(Table 1). An important observation on the 
etiological role of Mn in the parkinsonism 
in these young addicts is based on the fact 
that movement abnormalities are observed in 
ephedrone users in Eastern Europe and Russia 
where the chemical preparation uses potas-
sium permanganate as the oxidizing agent. 
However, a parkinsonian syndrome has not 
been observed in North America, where chro-
mate is used as the oxidizing agent rather than 
potassium permanganate (Selikhova et al. 
2008; Stepens et al. 2008). The most parsimo-
nious explanation is that Mn is the causative 
agent in this atypical form of parkinsonism.
Patients with liver disease. There is evi-
dence of parkinsonism associated with chronic 
liver disease. Patients with advanced cirrhosis 
have been documented with a form of par-
kinsonism with clinical symptoms similar 
to Mn-induced parkinsonism. This finding 
is likely because Mn is excreted in the bile, 
and in persons with chronic liver disease, 
the excretion of Mn is markedly impaired, 
with subsequent accumulation in the brain. 
The clinical symptoms associated with idio-
pathic PD, chronic liver disease, ephedrone 
abuse, and occupational exposures to Mn are 
described in Table 1. Some of the symptoms 
are common to those in PD, but there are 
significant differences. In conditions in which 
Mn is the most likely etiological agent for 
the parkinsonism, there is a rapid progres-
sion of the motor symptoms and early gait 
and postural impairment with focal dystonia 
(cock gait in worst cases). Further, there is an 
absence of resting tremor but an expression 
of action or postural tremor and no consistent 
asymmetry (Table 1). Elevated concentrations 
of Mn in basal ganglia structures have been 
measured in liver disease patients (Klos et al. 
2006) and are consistent with basal ganglia 
hyperintensive signals in T1-weighted MRI. 
Increased T1-weighted MRI hyperintensive 
signal is not observed in PD patients. From 
a clinical perspective, most persons who were 
occupationally exposed to Mn, users of ephed-
ron, and patients with liver disease and par-
kinsonism are not responsive or are minimally 
responsive to l-dopa therapy, the mainstay 
Table 1. Clinical symptoms of parkinsonism in idiopathic PD and in human conditions with elevated brain Mn concentrations.
Reference Category
Resting 
tremor
Action/
postural 
tremor Bradykinesia Rigidity
Postural 
instability
Gait 
disorder Dystonia Micrographia
Difficulty   walking 
backward, 
  turning, pull-test
Hypophonia,  
dysphonia/ 
dysarthria Falls
l-Dopa 
response
Jankovic 2008 IPD + + + + + + 
Secondary
+ + + Excellent
Lee 2000 Mn-O + + + + + + + + +
Yamada et al. 1986 Mn-O + + + + +
Cook et al. 1974 Mn-O + + + + + + + Minimal
Mena et al. 1967 Mn-O + + + + + + + + +
Huang 2007 (summary of 
Taiwan cohort)
Mn-O – + + + + + + + + + Minimal to none
Kessler et al. 2003 Mn-O + + + + + + + + + None
Kenangil et al. 2006 Welding + + + + + + None
Bowler et al. 2006 Welding + + + + + None
Josephs et al. 2005 Welding – + + + + + + Minimal
Racette et al. 2001 Welding + + + + Excellent
Sadek et al. 2003 Welding + + + + + + None
Meral et al. 2007 Ephedron Some + + + + + + + + None
Sikk et al. 2007 Ephedron + + + + +
de Bie et al. 2007 Ephedron + + + + + + + None
Sanotsky et al. 2007 Ephedron + + + + + + + + + None
Varlibas et al. 2009 Ephedron + + + + + Minimal to none
Stepens et al. 2008 Ephedron – + + + + + + + + + None
Selikhova et al. 2008 Ephedron + + + + + + + None
Colosimo and Guidi 2009 Ephedron + + + + + + + + None
Nagatomo et al. 1999 PN Some + + + + + +
Burkhard et al. 2003 LD  – + + + + + + + + + Minimal
Klos et al. 2006 LD  – + + + + None
Klos et al. 2005 LD + + + + + Minimal
Faviani et al. 2007 LD + + + + + + + + Partial
Kim et al. 2007 LD + + + + + + None
Schaumberg et al. 2006 Mn-O/LD – + – – + + + + Not tested
Abbreviations: IPD, idiopathic PD; LD, liver disease; Mn-O, occupational Mn exposure; PN, parenteral nutrition; secondary, later in time; some, minimal; +, the symptom was present; –, the symptom was not present; 
blank spaces, neither was indicated.Guilarte
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therapy that ameliorates the early movement 
abnormalities in PD (Table 1). Racette et al. 
(2001) noted an exception to this general 
observation; they found that welders with 
movement abnormalities (presumably from 
the Mn in the welding fume) had an excellent 
response to l-dopa therapy. However, a posi-
tive response to l-dopa therapy is not typical 
of Mn-induced parkinsonism but is represen-
tative of PD (Table 1). Further, their study has 
been criticized by several investigators (Ravina 
et al. 2001; Sadak and Schulz 2001).
Neuroimaging Studies in 
Idiopathic PD and Mn-Induced 
Parkinsonism
With the advent of molecular imaging tech-
niques in the 1980s, a number of neuro    imaging 
modalities have been used to understand the 
structural, cellular, and molecular changes that 
occur in neuro    logical and neuro    degenerative 
diseases. In PD and conditions associated 
with Mn-induced parkinsonism, three prin-
cipal neuro    imaging modalities have been 
used: T1-weighted MRI, SPECT, and PET. 
Structural MRI and magnetic resonance spec-
troscopy have also been used, but to a lesser 
extent, and are not discussed in this review.
In human conditions where Mn is the most 
likely etiological agent for the parkinsonism, a 
high percentage of the subjects exhibited a 
hyperintensive signal in T1-weighted MRI 
that is typically first observed in the globus pal-
lidus and in other basal ganglia structures such 
as the substantia nigra, caudate, and putamen 
(Figure 1, Table 2). This finding is because 
Mn is a paramagnetic metal that decreases the 
relaxation time in a T1-weighted MRI, which 
makes the signal hyperintensive. It should 
be noted that the basal ganglia T1-weighted 
MRI was normal in a small number of per-
sons who had been occupationally exposed to 
Mn, who had injected the ephedron prepara-
tion, or patients who had liver disease. This 
obsesrvation is most likely due to the fact that 
the T1-weighted MRI study was performed 
after a significant amount of time had passed 
from the time of exposure to the point when 
the Mn had been eliminated from the brain. 
Importantly, for patients with liver disease, 
the hyperintensive T1-weighted MRI signal in 
the basal ganglia is normalized after liver trans-
plantation (Aggarwal et al. 2006) that corrects 
the impairment in Mn excretion.
SPECT and PET studies have been used to 
assess nigrostriatal dopamine neuro  n terminal 
markers both in PD and in Mn-induced par-
kinsonism (Table 2). In PD patients, SPECT 
and PET studies have shown a progressive 
loss of DAT and VMAT2 and reduced dopa 
decarboxylase activity using [18F]-fluoro-dopa 
PET (Table 2). Importantly, PD patients have 
normal or increased levels of D2R in the stria-
tum (Table 2). A much more limited num-
ber of SPECT or PET studies are available 
for conditions associated with Mn-induced 
parkinsonism. The most extensive series of 
PET and SPECT human studies that exam-
ined presynaptic and postsynaptic dopamine 
terminal markers was performed over several 
years in four workers who had been occu-
pationally exposed to Mn in Taiwan. These 
workers exhibited movement abnormalities 
that were consistent with Mn-induced parkin-
sonism, and the findings from several clinical 
and neuro  imaging studies have been recently 
summarized by Huang (2007). In general, 
these occupationally exposed workers with 
Mn-induced movement abnormalities had 
normal [18F]-fluoro-dopa PET, normal DAT 
SPECT, and a small decrease in D2R PET. A 
decrease in D2R levels measured by PET also 
has been noted in another case report (Kessler 
et al. 2003) (Table 2). The findings summa-
rized by Huang (2007) are consistent with a 
normal synthesis of dopamine and normal lev-
els of DAT, both of which are significantly 
decreased in PD patients (Table 2). Further, 
in Mn-induced parkinsonism, Huang (2007) 
observed small but significantly decreased 
D2R signals, which is the opposite of what is 
observed in PD. These findings have provided 
evidence for a lack of nigrostriatal dopamine 
neuro  n degeneration in workers occupationally 
exposed to Mn who exhibit parkinsonism.
For the most part, available evidence from 
SPECT and PET studies of dopamine neu-
ron terminal markers in ephedron addicts 
and in liver disease patients have confirmed 
the lack of an effect of elevated brain Mn on 
dopa decarboxylase activity using [18F]-l-
dopa PET and on DAT levels in the stria-
tum (Colosimo and Guidi 2009; de Bie et al. 
2007; Kim et al. 2007; Selikhova et al. 2008; 
see Table 2). In one study, Kim et al. (2002) 
observed significant reductions in DAT levels 
measured by SPECT in two workers who had 
been occupationally exposed to Mn (Table 2). 
However, both subjects exhibited an excellent 
response to l-dopa therapy, which is typically 
not observed in Mn-induced parkinsonism 
(Table 1). Therefore, the possibility that these 
two subjects were PD cases with concurrent 
Mn exposure is high. Also, scientists gener-
ally assumed that decreased levels of DAT 
as measured by PET or SPECT are repre-
sentative of dopamine terminal loss in the 
striatum. Although this is clearly the case in 
PD patients where the neuro    pathology is 
well documented, this cannot be assumed in 
Mn-exposed subjects because studies have 
shown that Mn directly interacts with DAT. 
Chen et al. (2006) have shown that an acute 
dose of Mn produces a transient increase in 
DAT levels in the nonhuman primate stria-
tum. This transient increase is most likely due 
Table 2. Brain imaging studies in idiopathic PD and in human conditions that show elevated concentra-
tions of Mn in the brain.
Reference Category T1-MRI PET/SPECT
Blood or  
tissue Mn
Felicio et al. 2009 IPD NTD [18F]-fluoro-dopa PET NTD
DAT/SPECT/PET
VMAT2/PET (all significantly decreased)
Brooks et al. 1992 IPD NTD D2R/PET (increased or normal) NTD
Leenders 2003 IPD NTD D2R/PET (increased or normal) NTD
Huang 2007 (summary of 
Taiwan cohort)
Mn-O ↑ [18F]-fluoro-dopa PET (normal) ↑
DAT/SPECT (normal)
D2R/PET (small decrease)
Kim et al. 2002 Mn-O ↑ DAT/SPECT (decreased) ↑
Bowler et al. 2006 Welding ↑ NP ↑
Josephs et al. 2005 Welding ↑ NP ↑
Racette et al. 2001 Welding No signal [18F]-fluoro-dopa PET (major reduction) NP
Sadek et al. 2003 Welding ↑ NP ↑
Meral et al. 2007 Ephedron ↑ NP NP
de Bie et al. 2007 Ephedron ↑ [18F]-fluoro-dopa PET (minor reduction) ↑
Sanotsky et al. 2007 Ephedron ↑ NP NP
Varlibas et al. 2009 Ephedron ↑ NP ↑
Stepens et al. 2008 Ephedron ↑ NP ↑
Selikhova et al. 2008 Ephedron ↑ DAT/SPECT (normal) ↑
Colosimo and Guidi 2009 Ephedron Normal DAT/PET (normal) NP
Racette et al. 2005 LD ↑ [18F]-fluoro-dopa PET (major reduction) ↑
Burkhard et al. 2003 LD ↑ NP ↑
Klos et al. 2006 LD ↑ NP ↑
Klos et al. 2005 LD ↑ NP ↑
Faviani et al. 2007 LD ↑ NP ↑
Kim et al. 2007 LD ↑ DAT/SPECT (normal) ↑
Schaumberg et al. 2006 Mn-O/LD ↑ NP ↑
Kessler et al. 2003 Mn-O NP D2R/PET (decreased) NP
Abbreviations: IPD, idiopathic PD; LD, liver disease; Mn-O, occupational Mn exposure; NP, not performed; NTD, not 
typically done. PET/SPECT studies were done in the striatum (caudate and putamen). Arrows indicate increased 
T1-weighted MRI signal in the globus pallidus and other basal ganglia structures.Manganese-induced parkinsonism
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to acute inhibition of DAT, which produces 
an up-regulation of the protein. Consistent 
with this hypothesis, a direct inhibitory effect 
of Mn on radioligand binding to DAT was 
demonstrated in the same study. That is, Mn 
inhibited [3H]-WIN 35,428 binding to DAT 
in neuronal membranes from rat striatum. 
Thus, in the study by Kim et al. (2002) and in 
other SPECT and PET DAT imaging studies, 
it is possible that the decrease in DAT meas-
ured by SPECT may not be representative of 
DAT loss in the striatum (or, by inference, of 
dopamine terminal degeneration); rather, the 
decrease in DAT may reflect the ability of Mn 
to interfere with radioligand binding to DAT. 
For both of the Mn-exposed cases in the Kim 
et al. (2002) study, there had been a long his-
tory of Mn exposure. Thus, it is possible that 
a progressive accumulation of Mn occurred in 
the striatum that reached concentrations suf-
ficient to interfere with radioligand binding 
to DAT. This possibility can be explored in 
future studies because other dopamine termi-
nal markers such as VMAT2 can be imaged 
and are less likely to be influenced by elevated 
levels of Mn in the striatum.
In two studies, Racette et al. described 
reduced [18F]-fluoro-dopa PET signals in 
two welders (2001) and in a patient with 
liver disease (2005). These findings suggest 
the possibility of nigro  striatal dopamine 
neuron degeneration. However, other fac-
tors need to be considered. First, in the 2001 
study, 15 career welders were studied, and 
[18F]-fluoro-dopa PET was performed in only 
two of them. Second, all of the welders were 
responsive to l-dopa therapy, and this response 
is not consistent with Mn-induced parkin-
sonism. Third, none of the welders tested with 
T1-weighted MRI scans (8 of 15) exhibited 
a hyperintensive signal in the basal ganglia 
despite being career welders. Further, one of 
the two welders that had reduced [18F]-fluoro-
dopa uptake in the posterior putamen had a 
positive family history of PD, which suggests 
the possibility of a familial form of the disease. 
Taking all of the information together, the 
most parsimonious explanation is that the par-
kinsonism in these welders was not likely asso-
ciated with the Mn in the welding fumes. The 
second study (Racette et al. 2005) was a case 
report of a patient with alcoholic cirrhosis. 
This single subject had parkinsonian symptoms 
and elevated Mn in the blood and was respon-
sive to l-dopa therapy, a clinical response 
that has not been observed in Mn-induced 
parkinsonism. This case had a reduction in 
[18F]-fluoro-dopa uptake throughout the cau-
date and putamen; however, the caudate and 
posterior putamen ratio was more similar to 
the control subjects than to the PD controls.
In summary, the evidence from neuro  -
imaging studies have indicated that in different 
human conditions where Mn concentrations 
markedly increase in the brain to produce 
movement abnormalities, there is a lack of 
degeneration of the nigrostriatal dopaminergic 
terminals.
Neurochemical and 
Neuropathological Studies in PD 
and Mn-Induced Parkinsonism
As pointed out by Perl and Olanow (2007), a 
very limited number of autopsy studies have 
been performed on workers who were exposed 
to Mn or on persons with other related condi-
tions in which Mn was increased in the brain 
(Table 3). Most of the neuro    pathological stud-
ies associated with occupational Mn expo-
sures were performed in the early 1900s and 
lacked detailed examination of brain tissue. 
Neurochemical methods used in the early 
studies did not have the sensitivity and speci-
ficity available today. Nevertheless, most stud-
ies described marked changes in the globus 
pallidus of Mn-exposed individuals, with no 
remarkable effects on pigmented cells of the 
substantia nigra, which indicates a lack of an 
effect on dopamine cell bodies, the only mid-
brain neurons that contain melanin (Table 3). 
Neurochemical studies of the brains of patients 
with liver disease have confirmed for the most 
part the results from neuro    imaging studies: 
a significant decrease in D2R levels in the 
basal ganglia and no observed decrease in dop-
amine levels (Table 1). In one study, Mousseau 
et al. (1993) used in vitro auto  radiography 
and found decreased D2R levels in the glo-
bus pallidus and putamen with no change in 
D1-dopamine receptors (D1Rs) in the basal 
ganglia of patients with liver disease (Table 3).
In general, the available neuro    chemical and 
neuro    pathological evidence from subjects with 
increased Mn concentrations in the brain sug-
gests primary involvement of the globus palli-
dus, expressing the loss or shrinkage of neurons 
and glial cell activation. Consistent evidence 
has shown that D2R levels are decreased, and 
one study indicated no change in D1R. Most 
studies have indicated a lack of degeneration 
of midbrain dopamine neurons, which is con-
sistent with the majority of the neuro  imaging 
studies. Parenthetically, in the studies that 
indicated a loss or a shrinking of neurons in 
the globus pallidus or striatum of Mn-exposed 
subjects, no attempt has been made to identify 
the neuronal phenotype affected.
Behavioral, Neuroimaging, 
Neurochemical, and 
Neuropathological Evidence 
of Mn Neurotoxicity in 
Nonhuman Primates
Behavior. Experimental animals have been 
used to advance the understanding of Mn 
neuro  toxicity. Rodent studies are not 
described in this review because, unlike non-
human primates, they lack behavioral simi-
larities to humans and are less sensitive to Mn 
than are humans and nonhuman primates. 
Nonhuman primates have improved our 
understanding of the effects of Mn on motor 
function, in vivo brain chemistry, and neuro-
pathology (Table 4). Historically, nonhuman 
primate studies can be divided into two cat-
egories. The studies from the 1960s to the 
early 1990s used Mn doses that were consid-
erably higher than those used in studies from 
1995 to 2008 (Table 4). Most studies before 
1995 used cumulative doses > 300 mg Mn/kg 
body weight. These early studies did not use 
neuro  imaging techniques because of their 
more recent availability, with the exception 
of Newland and Weiss (1992) (Table 4), who 
administered very low doses of Mn and used 
T1-weighted MRI. Another important dif-
ference between the early studies and more 
recent ones has been the use of quantitative, 
advanced histological, neuro  chemical, and 
neuro  pathological techniques to analyze brain 
tissue. For example, some of the early studies 
Table 3. Neurochemical studies in human postmortem brain tissue.
Reference Category Neurochemistry/neuropathology
Bernheimer et al. 1973 Mn-O Putamen, pallidum, and red nucleus exhibited generalized 
astroglial activation
Mild degree of pallidal atrophy
Decreased DA levels in caudate, putamen, and SN
Lewy bodies in SN
Yamada et al. 1986 Mn-O Loss of nerve cells in the pallidum
Moderate decrease in the number of large nerve cells, and shrinking 
of cells
Pigmented cells of the SN were intact
Perl and Olanow 2007 Mn-O Describes studies from the early 1900s to 2004 indicating 
pathological effects in GP with no remarkable effects in SN
Butterworth et al. 1995 Liver disease Loss of D2R in GP
Mousseau et al. 1993 Liver disease [3H]-SCH 23390 autoradiography (D1R) unchanged in all basal 
ganglia regions tested
[3H]-Spiperone autoradiography (D2R) decreased in GP and 
putamen; no change in caudate
Bergeron et al. 1989 Liver disease DA/HPLC not changed in the caudate; HVA increased
Abbreviations: DA, dopamine; GP, globus pallidus; Mn-O, occupational Mn exposure; SN, substantia nigra.Guilarte
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Table 4. Behavioral, neuroimaging, and neurochemical studies in Mn-exposed nonhuman primates.
Reference Species Route ΣMn dose Behavior Neuroimaging Neuropathology/neurochemistry
Pentschew 
et al. 1963
Rhesus (5 
monkeys, only 1 
described)
im (Mn dioxide) 695 mg Mn/kg 
(calculated)
Excitability
Loss of postural stability
Falling upon jumping
Clumsiness
No cogwheel, tremor, or 
involuntary movements
ND Neuronal loss and gliosis in subthalamic 
nucleus and medial segment of GP
Gliosis in SN (?)
Atrophic nerve cells in lateral pallidum
Neff et al. 
1969
Squirrel monkey 
(control = 4; 
Mn-group A = 5; 
Mn-group B = 6)
sc (Mn dioxide) 379 mg Mn/kg in 
highest dose group 
(calculated)
Muscular rigidity
Impaired equilibrium
Tremors on intension
Impaired equilibrium
ND Decreased DA and NE in caudate
Chandra et al. 
1979
Rhesus (4) Oral 23,580 mg Mn/kg 
(MnCl2) (calculated)
ND ND Decreased DA in striatum and midbrain
Bird et al. 1984 Rhesus (4) Inhalation (Mn 
oxide)
30 mg Mn/m3 air 
(exposure rate)
No behavioral or 
neurological abnormalities
ND Decreased DA in caudate and GP but not in 
putamen or SN
Eriksson et al. 
1987
Rhesus (4) sc (Mn oxide) 1,543 mg Mn/kg 
(calculated)
Hyperactive tending to fall 
then hypoactive
Unsteady gait
Action tremor
Loss of power in limbs
Clumsy hands and feet 
movement
ND Severe neuronal loss and gliosis in GP, rest 
of brain appears normal
Decreased DA and DOPAC in putamen but 
not changed in the caudate
HVA levels normal in most animals
Decreased dopa decarboxylase activity in 
putamen of two-thirds of the animals
ChAT activity reduced in GP of all animals
GAD activity unaffected
Glutathione levels decreased in the striatum, 
GP, and SN of one third of the animals
Newland et al. 
1989
Long-tailed 
macaque (3)
iv and inhalation 
(MnCl2)
30–50 mg Mn/kg 
(injection)
ND ↑ T1-MRI hyperintensity basal 
ganglia
ND
Newland and 
Weiss 1992
Cebus (3) iv (MnCl2) 40–60 mg Mn/kg Action tremor ↑ T1-MRI hyperintensity basal 
ganglia
ND
Eriksson et al. 
1992a
Long-tailed 
macaque (3)
sc (Mn oxide) 333–444 mg Mn/kg 
(calculated)
Decreased activity in 1/2 of 
the Mn-exposed animals
ND DAT/autorad (decreased in caudate and 
putamen, no change in GP)
D1R/autorad (decreased in caudate and 
putamen, no change in GP)
D2R/autorad (no change in any region)
mAChR/autorad (no change in any region)
GABAaR/autorad (no change in any region)
Eriksson et al. 
1992b
Long-tailed 
macaque (2)
sc (Mn oxide) 680 mg Mn/kg 
(calculated)
Unsteady gait
Hypoactivity
Clumsiness of hands and 
feet
DAT/PET (60% decrease)
D2R/PET (40% decrease then 
normalized)
l-Dopa/PET (normal)
↑ T1-MRI hyperintensity in basal 
ganglia
ND 
Shinotoh et al. 
1995
Rhesus (3) iv (MnCl2) 71–87 mg Mn/kg Two animals hypoactive, 
one normal 
Not responsive to l-dopa
D2R/PET
l-Dopa/PET (normal)
FDG/PET (normal)
↑T1-MRI hyperintensity basal 
ganglia
Minimal cell loss and prominent gliosis in 
GP and lesser degree in SNpr (normal)
SNpc relatively spared
Olanow et al. 
1996
Rhesus (3) (same 
animals as 
Shinotoh et al. 
1995)
iv (MnCl2) 71–87 mg Mn/kg Two animals hypoactive, 
one normal
Not responsive to l-dopa
See Shinotoh et al. (1995) Minimal cell loss and prominent gliosis in 
GP and to lesser degree in SNpr
SNpc appeared normal
Striatal DA and HVA levels are normal in 
two affected animals
Dorman et al. 
2006
Rhesus (20) Inhalation Various levels of 
exposure
ND ↑ T1-MRI hyperintensity in basal 
ganglia
ND
Chen et al. 
2006
Baboon (2) sc and iv 10–100 mg Mn/kg 
(acute)
ND DAT/PET (transient increase) ND
Guilarte et al. 
2006a
Cynomolgus (3–5) iv 165.5 ± 4.7 mg Mn/kg 
(range = 152–174)
Subtle deficits in fine motor 
control 
Small decrease in activity
DAR/PET (significantly decreased)
DAT/PET (normal)
D2R/PET (normal)
DAT/autorad (normal)
D2R/autorad (normal)
TH/immunohistochemistry (normal)
DA-HVA/HPLC (normal)
Guilarte et al. 
2006b
Cynomolgus (4) iv 165.5 ± 4.7 mg Mn/kg 
(range = 152–174)
See Guilarte et al. 2006a ↑ T1-MRI hyperintensity in basal 
ganglia and other brain regions
MRS changes in regions outside 
basal ganglia
See Guilarte et al. (2006a)
Struve et al. 
2007
Rhesus (20) Inhalation  Various levels of 
exposure
ND ND DA-DOPAC-HVA/HPLC (normal)
Guilarte et al. 
2008
Cynomolgus (13; 
includes four 
animals from 
Guilarte et al. 
2006a)
iv (Mn sulfate) 68–250 mg Mn/kg See Schneider et al. 2006, 
2009
DAR/PET (significantly decreased)
DAT/PET (normal)
D2R/PET (small decrease)
DAT/autorad (normal)
D2R/autorad (normal)
D1R/autorad (normal)
CB1/autorad (normal)
TH/immunohistochemistry (normal)
DA-HVA/HPLC (normal)
Abbreviations: autorad, autoradiography; CB1, cannabinoid receptor 1; ChAT, choline acetyltransferase; DA, dopamine; DAR, dopamine release; DOPAC, 3,4-dihydroxyphenylacetic acid; D2R, dop-
amine receptor; FDG, fluorodeoxyglucose; GABAaR, γ-aminobutyric acid A receptor; GAD, glutamic acid decarboxylase; GP, globus pallidus; im, intramuscular; iv, intravenous; mAChR, muscarinic 
acetylcholine receptor; MRS, magnetic resonance spectroscopy; ND, not determined; NE, norepinephrine; sc, subcutaneous; SN, substantia nigra; SNpr, substantia nigra pars reticulata; TH, tyrosine 
hydroxylase. Arrows indicate increased T1-weighted MRI signal in the globus pallidus and other basal ganglia structures.Manganese-induced parkinsonism
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used gross anatomical examination of brain 
tissue, and the analysis of neuro  transmitter 
levels used colorimetric reactions that were 
prone to interference and lacked sensitiv-
ity compared with current state-of-the-art 
  techniques (Table 4).
From a behavioral perspective, early non-
human primate studies examined the effects 
of Mn on movement and coordination. It 
is clear from these studies that nonhuman 
primates exhibited movement abnormali-
ties similar to those in Mn-exposed humans 
(compare Tables 1 and 4), including loss of 
postural stability, excitability, hypoactivity, 
falling, muscular rigidity, tremors of inten-
sion or action tremor, unsteady gait, loss of 
power in limbs, and clumsy foot movement 
(Table 4). From 1995, studies used cumu-
lative Mn concentrations < 300 mg Mn/kg 
body weight and found more subtle move-
ment abnormalities, including hypoactivity, 
deficits in fine motor control, action tremor, 
and, more recently, deficits in working mem-
ory (Table 4). Consistent with the human lit-
erature, the Mn-induced motor abnormalities 
in nonhuman primates were not responsive to 
l-dopa therapy (Shinotoh et al. 1995).
Neurochemistry. The early nonhuman 
primate studies of Mn exposure described 
decreased levels of dopamine in the caudate 
(Neff et al. 1969), striatum and midbrain 
(Chandra et al. 1979), caudate and globus 
pallidus but not in the putamen or substantia 
nigra (Bird et al. 1984), and putamen but no 
change in the caudate (Eriksson et al. 1987). 
Some relevant comments are important to 
put these results in perspective. First, in the 
study by Neff et al. (1969), the monkeys in 
group A were injected with single doses of 
200 mg Mn oxide on two different occa-
sions. The report indicated that “2 weeks 
following the first injection, 1 control and 
4 MnO2 treated monkeys died.” This was a 
highly unusual event and makes one question 
the health status of these animals prior and 
during treatment. They reported a signifi-
cant decrease of dopamine in the caudate of 
group A monkeys, and a less severe dopamine 
deficit but still a significant one in another 
group of Mn-exposed animals that received a 
third injection (group B).
In another study, Bird et al. (1984) exposed 
monkeys, via inhalation, to a 30 mg/m3 con-
centration of Mn for 5 days/week, 6 hr/day, 
for 2 years. They found decreased levels of 
dopamine in the caudate and globus pallidus 
but not in the putamen and substantia nigra. 
Chandra et al. (1979) exposed male rhesus 
monkeys orally (MnCl2 at 20 mg/kg/day) for 
18 months and reported significant reduc-
tions in dopamine concentrations in the stria-
tum (–42%) and the midbrain (–15%). In 
this study, two observations were important. 
First, the brain was dissected, and the different 
regions were frozen at –20°C. For dopamine 
analysis, this temperature is not the most 
appropriate for storing fresh tissue, because 
dopamine autooxidizes readily. Second, the 
dopamine recovery for the method used was 
less than desirable and ranged from 72–84%. 
Although a comparison of control and 
treated dopamine tissue content is still pos-
sible, often in these early studies, the control 
and Mn-treated animals were euthanized at 
different times; thus potential differences in 
dopamine tissue content could result from dif-
ferences in storage time and conditions. For 
example, in the study by Neff et al. (1969), 
Mn-exposed animals that received a higher 
cumulative Mn dose exhibited less dopamine 
loss than did animals with a lower dose whose 
tissues were stored for a longer time.
Eriksson et al. (1987) measured reduced 
concentrations of dopamine in the putamen 
and globus pallidus but not in the caudate, 
although one of the three animals analyzed did 
express a decrease in dopamine content in the 
caudate. An observation in the Eriksson et al. 
(1987) study that has relevance to a mecha-
nism of action of Mn is that in the brains of 
these monkeys, in which they measured sig-
nificant decrements in tissue dopamine con-
centration, they found no significant effect 
on glutathione concentrations in two of the 
three monkeys examined. In general, these 
early studies demonstrate differences in basal 
ganglia regions where dopamine concentra-
tions appear to be decreased and the regional 
pattern does not follow the well-characterized 
loss of dopamine in idiopathic PD (Dauer and 
Przedborski 2003; Felicio et al. 2009).
The most consistent observation of these 
early studies was that Mn produced morpho-
logical changes in the globus pallidus, sub-
thalamic nuclei, and substantia nigra pars 
reticulata, whereas the SNpc remained intact 
(Table 4). More recent studies (after 1995) that 
have used cumulative Mn doses < 300 mg/kg 
and state-of-the-art high-  performance liquid 
chromatography (HPLC) with electrochemi-
cal detection analytical methods have provided 
no evidence of changes in dopamine concen-
trations in the caudate and putamen (Guilarte 
et al. 2006a, 2008; Olanow et al. 1996; Struve 
et al. 2007) (Table 4).
In vitro autoradiography. In vitro quanti-
tative receptor autoradiography has been used 
to examine dopamine neuron markers in the 
brain of Mn-exposed nonhuman primates 
(Table 4). The groups headed by Eriksson in 
Sweden (1992a) and by Guilarte in the United 
States (2006a, 2008), have used this approach 
extensively because not only is it quantitative, 
it also offers exquisite anatomical information 
with high resolution. Eriksson et al. (1992a) 
performed receptor autoradiography stud-
ies in the basal ganglia of monkeys exposed 
to 0.1 g Mn/month for 26 months. They 
indicated that this dosing regimen was compa-
rable with what workers might inhale in dusty 
environments. They found that the binding of 
[3H]-mazindol to DAT (the presumed target, 
but see below) was reduced by 75% in the 
caudate and putamen of Mn-exposed animals. 
However, there were technical problems that 
need to be discussed: a) The authors stated 
that the level of nonspecific [3H]-  mazindol 
binding in the caudate and putamen was 
50% and 60%, respectively. This level of non-
specific binding was very high, so the specific 
binding signal-to-noise (nonspecific binding) 
ratio was very low. Typically in this type of 
assay, one wants a low level of nonspecific 
binding, in the range of 10–15% of total 
binding. b) [3H]-Mazindol is known to bind 
to other monoaminergic uptake sites besides 
DAT (May et al. 1994). To ensure that one is 
selectively measuring DAT, an antagonist for 
the other monoaminergic uptake sites should 
be included in the assay. This procedure was 
not performed by Eriksson et al. (1992a); thus, 
the effect of Mn on the [3H]-mazindol autora-
diography results were a combination of DAT 
and other monoaminergic uptake sites. c) As 
pointed out, even if [3H]-mazindol was made 
selective for DAT by including antagonists for 
other monoaminergic transporters, a reduc-
tion in [3H]-mazindol binding to DAT would 
not necessarily reflect dopamine terminal loss, 
but it could represent a competitive inhibition 
of Mn with radioligand binding to DAT as 
shown by Chen et al. (2006). Parenthetically, 
Eriksson et al. (1992a) also found a significant 
decrease in [3H]-SCH 23390 binding to D1R 
in the caudate and putamen with no change in 
[3H]-spiperone binding to D2R in the same 
regions. These results were opposite to what 
Eriksson et al. (1992b) and Guilarte et al. 
(2008) reported with in vivo PET imaging and 
in vitro autoradiography—that is, decreased 
D2R and no effect on D1R.
Guilarte et al. (2006a, 2008) have exam-
ined the largest cohort of Mn-exposed non-
human primates using in vivo and in vitro 
methods (see Table 4). In a preliminary 
report in which four Mn-exposed animal 
were used, they found no significant effect 
of Mn exposure (mean cumulative Mn 
dose, 165.5 mg Mn/kg body weight; range, 
152–174 mg Mn/kg body weight) on DAT 
or D2R receptor levels using auto  radio-
graphy or tyrosine hydroxylase immuno-
histo  chemistry, or on the concentration of 
dopamine and its metabolite homovanillic 
acid (HVA) measured by HPLC with elec-
trochemical detection in the caudate or puta-
men, relative to naive controls (Guilarte et al. 
2006a). These findings clearly indicated the 
lack of an effect of this cumulative Mn dose 
on the nigrostriatal dopaminergic system (but 
see “Neuroimaging studies,” below). In a sub-
sequent publication with a larger number of Guilarte
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Mn-exposed animals, Guilarte et al. (2008) 
essentially found the same results. Further, 
Mn exposure had no effect on D1R or can-
nabinoid receptor 1 levels in the basal ganglia. 
This latter study not only included a naive 
control group in which the animals did not 
receive Mn or neuro  imaging studies, but it 
also included an imaged control group in 
which the neuro  imaging studies were done 
without Mn exposure. The inclusion of an 
imaged control group was essential because 
one of the longitudinal PET studies included 
the administration of amphetamine (Guilarte 
et al. 2006a, 2008), a psychostimulant that 
depletes dopamine levels and down-regulates 
DAT. This control group provided valu-
able information for assessing the effect of 
amphetamine alone. Although several of the 
dopamine neuron markers that were analyzed 
postmortem, such as dopamine and DOPAC 
(3,4-dihydroxyphenylacetic acid) in the puta-
men, DAT and VMAT2 in the caudate and 
putamen and D2R in the putamen were sig-
nificantly lower in Mn-exposed animals than 
in naive controls; they were not different from 
all controls when the imaged control group 
was included. The values for these parameters 
in the imaged control animals were actually 
lower than those for the Mn-exposed animals. 
The fact that studies of Mn-exposed animals 
that received amphetamine with PET had 
higher levels of these dopamine markers than 
did imaged controls that received the same 
amphetamine with PET but no Mn suggests 
that Mn has an “antagonistic effect” on the 
action of amphetamine on these dopamin-
ergic markers. Because this action on dop-
aminergic markers is mediated by DAT, these 
results provide evidence that Mn interacts 
directly with DAT and are consistent with 
other studies that indicate an interaction of 
Mn with DAT (Anderson et al. 2007; Chen 
et al. 2006; Ingersoll et al. 1999).
Neuroimaging studies: MRI and PET. 
Similar to the studies involving humans 
exposed to Mn, several investigators have 
performed neuro  imaging studies of non-
human primates to examine the distribution 
of Mn in the brain by T1-weighted MRI 
and brain chemistry changes using PET. The 
T1-weighted MRI studies (Newland et al. 
1989; Newland and Weiss 1992) (Table 4) 
showed that Mn first accumulates in the 
globus pallidus and produces a hyperinten-
sive signal in T1-weighted MRI even at rela-
tively low doses of Mn. Thus, it is a sensitive 
method for detecting small increases in brain 
Mn concentrations. These findings have been 
confirmed by other investigators, and subse-
quent studies have shown that although the 
basal ganglia is one of the first to accumulate 
Mn, other brain structures also accumulate 
the metal, albeit to a lesser extent (Dorman 
et al. 2006; Ingersoll et al. 2006b).
PET imaging in nonhuman primates 
exposed to Mn was first performed by 
Eriksson (1992b) (Table 4). They studied two 
monkeys exposed to Mn for 16 months that 
received [11C]-nomifensine PET to measure 
DAT (although this ligand also recognizes 
other monoaminergic transporters), [11C]-
raclopride PET for D2R, and [11C]-l-dopa 
for l-dopa decarboxylase activity. They found 
a progressive decrease in [11C]-nomifensine 
binding as a function of cumulative dose in 
both animals. One of the animals had a tran-
sient decrease in [11C]-raclopride binding to 
D2R that returned to baseline by the end 
of the exposure period, and no effect of Mn 
treatment on [11C]-l-dopa PET was observed. 
These studies indicate that dopamine neurons 
are not degenerating, but there is a poten-
tial loss of dopamine terminals based on the 
[11C]-nomifensine PET. However, a firm 
conclusion that chronic Mn results in the 
loss of DAT and presumably dopamine neu-
ron terminals in the striatum cannot be made 
because [11C]-nomifensine is not a selective 
DAT ligand and because Mn can directly 
inhibit ligand binding to DAT.
Shinotoh et al. (1995) performed PET 
studies in three monkeys (not all monkeys 
received the three different types of PET stud-
ies) that were chronically treated with Mn. 
These investigators found no significant effect 
of Mn on [18F]-fluoro-l-dopa PET, [11C]-
raclopride PET, or [18F]-deoxyglucose PET 
despite the fact that the animals exhibited 
hypoactivity (Table 4). Thus, their work is 
also consistent with the lack of degeneration 
of nigrostriatal dopaminergic neurons.
Neuroimaging studies: new PET findings. 
Since the study by Shinotoh et al. (1995), 
there has been a lack of neuro  imaging studies 
to examine the effects of chronic Mn expo-
sure on brain chemistry in nonhuman pri-
mates. Guilarte et al. (2006a, 2006b, 2008) 
have recently undertaken a large multidisci-
plinary effort to more broadly examine the 
longitudinal effects of chronic Mn exposure 
on behavior, in vivo brain chemistry, and 
brain pathology in the same animals (only 
the PET studies related to the dopaminergic 
system were described here). They performed 
PET studies of presynaptic and postsynaptic 
“structural proteins” such as DAT ([11C]-
methylphenidate as the PET radioligand) 
and D2R ([11C]-raclopride as the PET radio-
ligand) to examine various markers of the 
dopaminergic synapse. A PET study to assess 
dopaminergic function was also included. 
Although [18F]-fluoro-dopa PET is a perfectly 
valid and useful functional marker of dop-
aminergic activity, this method interrogates 
the ability of dopamine neurons to synthe-
size dopamine, and it may indirectly measure 
the dopamine-releasing capacity of dopamine 
neurons. Guilarte et al. (2006a, 2008) used 
a more direct method to assess in vivo dop-
amine release using a bolus plus continuous 
infusion of [11C]-raclopride (D2R ligand) 
with amphetamine challenge (Zhou et al. 
2006). This type of PET study is based on the 
ability of endogenous dopamine (released by 
the administration of amphetamine) to com-
pete with the binding of [11C]-raclopride to 
D2R (Laruelle 2000). An animal with a high 
capacity to release dopamine will produce a 
large decrease in the amount of [11C]-raclo-
pride uptake in the striatum, whereas an ani-
mal with a low capacity will produce a smaller 
change or no change. These studies showed 
that the most significant effect of chronic Mn 
at all of the cumulative doses of Mn admin-
istered was a marked inhibition (> 50% on 
average) of in vivo dopamine release in the 
striatum measured by PET (Guilarte et al. 
2006a, 2008) (Table 4). The effect of Mn 
on in vivo dopamine release was observed in 
the absence of a change in DAT levels and 
with a small but significant decrease on D2R 
levels in the striatum (Guilarte et al. 2008). 
Therefore, consistent with human and other 
nonhuman primate studies, this work also 
showed a lack of dopamine neuron degen-
eration. However, these studies provided new 
information: although chronic Mn exposure 
did not result in dopamine neuron degenera-
tion, dopamine neurons were dysfunctional 
because they had a reduced capacity to release 
dopamine. Neurochemical studies in the 
brain of the same animals that received PET 
studies showed that the marked effect of Mn 
on in vivo dopamine release measured by PET 
was not due to a reduction in tissue dopamine 
levels, because dopamine concentrations were 
not significantly different from all controls 
(Guilarte et al. 2006a, 2008). It appears that 
the deficit of in vivo dopamine release is asso-
ciated with the ability of Mn to disrupt pre-
synaptic release mechanisms.
Conclusions
The available evidence from human and non-
human primate studies using behavioral, 
neuro  imaging, neuro  chemical, and neuro-
pathological end points provides strong sup-
port to the hypothesis that, although excess 
levels of Mn accumulation in the brain results 
in an atypical form of parkinsonism, this clini-
cal outcome is not associated with the degen-
eration of nigrostriatal dopaminergic neurons 
as is the case in PD. In fact, the new evidence 
suggests that it may be the dysfunction of this 
system or the inability to release dopamine 
that produces the movement abnormalities 
documented in Mn-exposed subjects. This 
new finding is consistent with the fact that 
l-dopa therapy does not provide a benefit to 
the Mn-induced movement abnormalities as it 
does in PD (Lu et al. 1994) (Table 1). This is 
because Mn-induced motor dysfunction does Manganese-induced parkinsonism
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not seem to be a problem of decreased synthe-
sis or concentration of dopamine in presynaptic 
terminals, but rather a problem of the ability to 
release the available dopamine. These findings 
provide a starting point and a new avenue of 
research to delineate a putative mechanism of 
Mn-induced movement abnormalities.
Although the latest research clearly suggests 
that the effects of Mn on presynaptic aspects of 
the dopaminergic synapse need further explo-
ration, delineating its effects on postsynaptic 
proteins of the dopaminergic synapse or other 
neuronal systems downstream and on the role 
of glial cells is essential in order to achieve a 
greater understanding of the neuro  toxicity of 
Mn. The continued use of neuro  imaging tech-
niques that have already been used to study Mn 
neuro  toxicity, as well as some others such as 
diffusion tensor imaging, are also likely to pro-
vide new information. Ultimately, the most sig-
nificant studies in understanding Mn-induced 
parkinsonism are those in humans. From this 
perspective, persons who inject high doses of 
Mn in the ephedron preparations and workers 
who are occupationally exposed to moderate 
levels of Mn are cohorts in which compre-
hensive neuro  logical assessments along with 
neuro  imaging studies can provide longitudi-
nal information about Mn neuro  toxicity, its 
reversibility, and the usefulness of therapeutic 
strategies. Finally, although the preponderance 
of the behavioral, neuro  imaging, and neuro-
pathological evidence indicates that chronic 
Mn exposure does not cause degeneration of 
nigrostriatal dopamine neurons and PD, the 
parkinsonism and other neuro  logical effects 
resulting from chronic Mn exposure are highly 
debilitating, and it should not be treated with 
any less importance.
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